Skip to main content
Signal8
Launch Terminal

Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc.

NASDAQ:TSHAHealthcare
-2.13%$4.13
AH$4.21+1.94%vs close
Mkt Cap$1.35B
Float290.51M
O/S325.83M
Vol
$ Vol
RVOL
Inst Own92.0%
SI17.6%
Earnings
Dilution
Taysha Gene Therapies, Inc. logoNASDAQ:TSHA$4.13-2.13%
Pipeline4 lead-sponsored trials·3 active0 completed(1 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Active, not recruiting

    A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)

    TSHA-102

    Rett Syndrome

    Enrollment
    17
    Start
    Mar 2023
    Primary Completion
    Jun 2031est.
    Completion
    Jun 2031est.
    NCT05606614
  • Phase 3
    Active, not recruiting

    Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome

    TSHA-102

    Rett Syndrome

    Enrollment
    4
    Start
    May 2026
    Primary Completion
    Jun 2031est.
    Completion
    Jun 2031est.
    NCT07480564
  • Phase 1/2
    Active, not recruiting

    Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)

    TSHA-102

    Rett Syndrome

    Enrollment
    6
    Start
    Dec 2023
    Primary Completion
    Nov 2028est.
    Completion
    Nov 2031est.
    NCT06152237
  • Observational
    Withdrawn

    A Study of the Natural Course of SURF1 Deficiency

    None (Observational study)

    Leigh Syndrome

    Enrollment
    0
    Start
    May 2022
    Primary Completion
    May 2022
    Completion
    May 2022
    NCT05277363
Search ClinicalTrials.gov for “Taysha Gene Therapies”